Abstract
Enhanced nucleoside metabolism is one of the hallmarks of cancer. Uridine-cytidine kinase 2 (UCK2) is a rate-limiting enzyme of the pyrimidine salvage synthesis pathway to phosphorylate uridine and cytidine to uridine monophosphate (UMP) and cytidine monophosphate (CMP), respectively. Recent studies have shown that UCK2 is overexpressed in many types of solid and hematopoietic cancers, closely associates with poor prognosis, and promotes cell proliferation and migration in lung cancer and HCCs. Although UCK2 is thought to catalyze sufficient nucleotide building blocks to support the rapid proliferation of tumor cells, we and other groups have recently demonstrated that UCK2 may play a tumor-promoting role in a catalytic independent manner by activating oncogenic signaling pathways, such as STAT3 and EGFR-AKT. By harnessing the catalytic activity of UCK2, several cytotoxic ribonucleoside analogs, such as TAS-106 and RX-3117, have been developed for UCK2-mediated cancer chemotherapy. Moreover, we have demonstrated that the concurrent targeting of the catalytic dependent and independent features of UCK2 could synergistically inhibit tumor growth. These findings suggest that UCK2 may serve as a potential therapeutic target for cancer treatment. In this mini-review, we introduced the genomic localization and protein structure of UCK2, described the role of UCK2 in tumor development, discussed the application of UCK2 in anti-tumor treatment, and proposed concurrent targeting of the catalytic and non-catalytic roles of UCK2 as a potential therapeutic strategy for cancer treatment.
Introduction
Rapidly dividing cancer cells require a constant supply of nucleotides for DNA replication and RNA transcription. While de novo synthesis is a primary source, the pyrimidine salvage pathway—specifically the enzyme Uridine-cytidine kinase 2 (UCK2)—plays a critical role in meeting this demand. UCK2 is frequently overexpressed in solid tumors, such as lung and liver cancer, where it acts as a metabolic engine. However, emerging evidence suggests that UCK2 is a "moonlighting" protein with dual roles: it not only drives metabolism but also acts as a non-catalytic signaling scaffold that promotes metastasis.
Structural Basis of UCK2 Function
UCK2 is significantly more efficient than its ubiquitously expressed sibling, UCK1, with a catalytic efficiency 15–20 times higher. This disparity is rooted in their structural differences. The human UCK2 monomer features a core five-stranded parallel $\beta$-sheet flanked by $\alpha$-helices. Key residues, including His117 and Tyr112, dictate substrate specificity, while Asp62, Ser34, and Glu135 coordinate the essential magnesium ion in the active site.
The Dual Role: Metabolism vs. Signaling
The oncogenic potential of UCK2 is decoupled into metabolic and non-metabolic functions. Its catalytic activity supports proliferation by providing nucleotide building blocks. In contrast, its non-metabolic role drives migration and invasion. For example, UCK2 interacts with the Epidermal Growth Factor Receptor (EGFR), preventing its degradation and sustaining the AKT signaling pathway. Functional mutagenesis using "catalytic-dead" mutants (e.g., UCK2$^{D62A}$) has confirmed that UCK2 can promote metastasis even when its enzymatic function is disabled.
Therapeutic Implications and "Dual-Targeting"
UCK2's high expression in tumors makes it an ideal target for chemotherapy. It is the primary enzyme responsible for activating prodrugs like RX-3117, creating a "collateral sensitivity" where the tumor's metabolic dependency becomes its vulnerability. However, targeting metabolism alone may leave the pro-metastatic signaling functions intact. Therefore, a "dual-targeting" strategy—combining UCK2-activated cytotoxic analogs with signaling inhibitors (e.g., EGFR inhibitors)—is proposed to synergistically inhibit tumor growth and spread.
Conclusion and Future Directions
UCK2 is a consistent biomarker for poor prognosis across multiple cancers. While its dual roles are well-documented in pre-clinical models, several challenges remain. A formal pan-cancer analysis using TCGA data is needed, and the upstream regulatory networks driving UCK2 overexpression (such as hypoxia or m6A methylation) require further mapping. Ultimately, clinical trials are necessary to validate the efficacy of concurrent targeting of UCK2’s catalytic and non-catalytic roles in human patients.
Summary updated